Literature DB >> 19435602

E. coli expression and purification of human and cynomolgus IL-15.

Alison Ward1, Malcolm Anderson, Robert I Craggs, Justine Maltby, Caroline Grahames, Rick A Davies, Donna Finch, Debbie Pattison, Heather Oakes, Philip R Mallinder.   

Abstract

The physiological activities of Interleukin-15 (IL-15) suggest that it could be useful as an immunomodulator to activate the innate immune system, however, the expression and purification yields of recombinant mature IL-15 have typically been low. In this report, a method was optimised to generate milligram quantities of this cytokine. Human IL-15 with an N-terminal (His)(6)-tag was expressed in Escherichia coli as an insoluble protein. The IL-15 material was purified from other cellular proteins by dissolution in 6M guanidine HCl, followed by Ni-NTA chromatography in a buffer containing 8M urea. Use of a multi-component screen identified the optimal conditions for folding (His)(6)-tagged human IL-15 and the method was scaled up to produce milligram quantities of folded material in its native conformation, with two intra-molecular disulphides as determined by electrospray mass spectrometry. Mature IL-15 was generated by cleavage with recombinant enterokinase, which was subsequently removed by Ni-NTA chromatography. Identical methods were used to produce mature cynomolgus monkey (Macaca fascicularis) IL-15 in similar quantities. Human and cynomolgus IL-15 were both active in two IL-15 dependent assays; mouse CTLL2 cell proliferation and human and cynomolgus CD69 upregulation on CD3(-) CD8+ lymphocytes in whole blood. Despite being 96% identical at the amino acid level the human IL-15 was 10-fold more potent than the cynomolgus IL-15 in both assays. The methods described here are useful for producing both mature IL-15 proteins in sufficient quantity for in vivo and in vitro studies, including X-ray crystallography.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435602     DOI: 10.1016/j.pep.2009.05.004

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  8 in total

1.  Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.

Authors:  Vinay V Vyas; Dominic Esposito; Terry L Sumpter; Trevor L Broadt; James Hartley; George C Knapp; Wei Cheng; Man-Shiow Jiang; John M Roach; Xiaoyi Yang; Steven L Giardina; George Mitra; Jason L Yovandich; Stephen P Creekmore; Thomas A Waldmann; Jianwei Zhu
Journal:  Biotechnol Prog       Date:  2011-12-09

2.  Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.

Authors:  David F Nellis; Dennis F Michiel; Man-Shiow Jiang; Dominic Esposito; Richard Davis; Hengguang Jiang; Angela Korrell; George C Knapp; Lauren E Lucernoni; Roy E Nelson; Emily M Pritt; Lauren V Procter; Mark Rogers; Terry L Sumpter; Vinay V Vyas; Timothy J Waybright; Xiaoyi Yang; Amy M Zheng; Jason L Yovandich; John A Gilly; George Mitra; Jianwei Zhu
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

3.  IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.

Authors:  Kai-ping Han; Xiaoyun Zhu; Bai Liu; Emily Jeng; Lin Kong; Jason L Yovandich; Vinay V Vyas; Warren D Marcus; Pierre-Andre Chavaillaz; Christian A Romero; Peter R Rhode; Hing C Wong
Journal:  Cytokine       Date:  2011-10-22       Impact factor: 3.861

4.  Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules.

Authors:  Richard L Wong; Bai Liu; Xiaoyun Zhu; Lijing You; Lin Kong; Kai-Ping Han; Hyung-Il Lee; Pierre-Andre Chavaillaz; Moonsoo Jin; Yi Wang; Peter R Rhode; Hing C Wong
Journal:  Protein Eng Des Sel       Date:  2010-12-21       Impact factor: 1.650

5.  Development of Stable Chimeric IL-15 for Trans-Presentation by the Antigen Presenting Cells.

Authors:  Manoj Patidar; Naveen Yadav; Sarat K Dalai
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

6.  New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.

Authors:  Cavan P Bailey; Tulin Budak-Alpdogan; Christopher T Sauter; Michelle M Panis; Cihangir Buyukgoz; Emily K Jeng; Hing C Wong; Neal Flomenberg; Onder Alpdogan
Journal:  Oncotarget       Date:  2017-07-04

7.  Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.

Authors:  Qiyue Hu; Xin Ye; Xiangdong Qu; Dongbing Cui; Lei Zhang; Zhibin Xu; Hong Wan; Lianshan Zhang; Weikang Tao
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

Review 8.  Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection.

Authors:  Olivia Harwood; Shelby O'Connor
Journal:  Viruses       Date:  2021-09-02       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.